Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weaver, D. F.
Right arrow Articles by Ing, V. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weaver, D. F.
Right arrow Articles by Ing, V. W.
NEUROLOGY 1988;38:144
© 1988 American Academy of Neurology

Eosinophil-induced neurotoxicity

Axonal neuropathy, cerebral infarction, and dementia

D. F. Weaver, MD, PhD, L. P. Heffernan, MD, FRCP(C), R. A. Purdy, MD, FRCP(C) and V. W. Ing, MD, FRCP(C)

Neurological Investigation Unit, Department of Neurology (Drs. Weaver, Heffernan, and Purdy), Dalhousie University, and Haematology Service, Department of Medicine (Dr. Ing), Victoria General Hospital, Halifax, Nova Scotia, Canada.

Although beneficial in allergic and parasitic disease, eosinophils exert nonspecific toxic effects upon host tissues, especially the central and peripheral nervous systems. Eosinophil-induced neurotoxicity is characterized by axonal neuropathy, cerebral infarction, and dementia. Eosinophilderived cytotoxic proteins are fundamental to the pathogenesis of this disorder.

Address correspondence and reprint requests to Dr. Weaver, Neurological Investigation Unit, Victoria General Hospital, Halifax, Nova Scotia, B3H 2Y9, Canada.

Received January 28, 1987. Accepted for publication in final form April 8, 1987.




This article has been cited by other articles:


Home page
 BloodHome page
J. Gotlib, J. Cools, J. M. Malone III, S. L. Schrier, D. G. Gilliland, and S. E. Coutre
The FIP1L1-PDGFR{alpha} fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management
Blood, April 15, 2004; 103(8): 2879 - 2891.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
C. Armstrong, T. Lewis, M. D'Esposito, and B. Freundlich
Eosinophilia-myalgia syndrome: selective cognitive impairment, longitudinal effects, and neuroimaging findings
J. Neurol. Neurosurg. Psychiatry, November 1, 1997; 63(5): 633 - 641.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
L. M. Tolander, C. R. Bamford, M. T. Yoshino, S. Downing, and G. Bryan
Neurologic Complications of the Tryptophan-Associated Eosinophilia-Myalgia Syndrome
Arch Neurol, April 1, 1991; 48(4): 436 - 438.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.